Your browser is no longer supported. Please, upgrade your browser.
Settings
YMTX [NASD]
Yumanity Therapeutics, Inc.
Index- P/E- EPS (ttm)-16.25 Insider Own0.60% Shs Outstand10.20M Perf Week-4.60%
Market Cap88.49M Forward P/E- EPS next Y-6.04 Insider Trans0.00% Shs Float8.93M Perf Month-15.02%
Income-51.20M PEG- EPS next Q-1.13 Inst Own42.20% Short Float0.80% Perf Quarter-7.73%
Sales12.50M P/S7.08 EPS this Y6.70% Inst Trans0.02% Short Ratio0.49 Perf Half Y-48.43%
Book/sh4.03 P/B2.16 EPS next Y-38.50% ROA- Target Price36.67 Perf Year-58.92%
Cash/sh5.47 P/C1.59 EPS next 5Y- ROE- 52W Range8.21 - 26.20 Perf YTD-48.76%
Dividend- P/FCF- EPS past 5Y2.40% ROI-76.60% 52W High-66.22% Beta0.51
Dividend %- Quick Ratio3.30 Sales past 5Y9.80% Gross Margin- 52W Low7.80% ATR0.60
Employees46 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)41.75 Volatility5.96% 6.41%
OptionableYes Debt/Eq0.37 EPS Q/Q69.90% Profit Margin- Rel Volume1.19 Prev Close8.71
ShortableYes LT Debt/Eq0.25 Earnings- Payout- Avg Volume147.26K Price8.85
Recom1.70 SMA20-4.69% SMA50-11.07% SMA200-37.46% Volume30,592 Change1.61%
Oct-14-21 07:00AM  
Sep-09-21 04:15PM  
08:00AM  
Aug-16-21 07:00AM  
Aug-12-21 04:15PM  
Aug-06-21 07:00AM  
Jun-14-21 07:00AM  
May-27-21 07:00AM  
May-17-21 04:05PM  
May-13-21 07:00AM  
May-12-21 08:00AM  
May-04-21 08:00AM  
Apr-28-21 08:07PM  
Apr-22-21 07:00AM  
Apr-13-21 08:00AM  
Apr-06-21 08:00AM  
Mar-31-21 08:48AM  
Mar-23-21 09:41AM  
Mar-09-21 08:00AM  
Mar-02-21 04:05PM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.